Special Issue

Targeted Drug Delivery Systems for Treating Gastrointestinal Inflammatory Diseases

Message from the Guest Editor

The gastrointestinal tract (GIT), which includes all the digestive systems extending from the mouth to the anus, is often vulnerable to inflammation. Gastrointestinal inflammatory diseases including periodontitis, gastric ulcer, gastritis, Crohn's disease. and ulcerative colitis are significant sources of diseaseassociated morbidity and mortality as well as pain and disability worldwide. However, most of the drugs which are currently used to treat gastrointestinal inflammatory diseases do not selectively target the region where inflammation occurs, thus leading to frequent dosing and potential adverse effects which can negatively affect patient compliance. In this sense, there is an urgent need for innovative delivery systems that deliver a drug to the site of inflammation, prolong local drug availability, improve therapeutic efficacy, and reduce drug side effects. This Special Issue of *Pharmaceutics* highlights the recent progress of targeted delivery systems that can effectively treat gastrointestinal inflammatory diseases. Any innovative systems that deliver a therapeutic agent to inflammatory regions in the GIT will be welcome.

Guest Editor

Prof. Dr. Jin-Wook Yoo

College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea

Deadline for manuscript submissions

closed (10 November 2021)



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/62211

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/ pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

